This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stapleton, J T Articles by Lemon, S M Search for Related Content PubMed PubMed Citation Articles by Stapleton, J T Articles by Lemon, S M

Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus.

ABSTRACT

Hepatitis A virus is an hepatotrophic human picornavirus which demonstrates little antigenic variability. To topologically map immunogenic sites on hepatitis A virus which elicit neutralizing antibodies, eight neutralizing monoclonal antibodies were evaluated in competition immunoassays employing radiolabeled monoclonal antibodies and HM-175 virus. Whereas two antibodies (K3-4C8 and K3-2F2) bound to intimately overlapping epitopes, the epitope bound by a third antibody (B5-B3) was distinctly different as evidenced by a lack of competition between antibodies for binding to the virus. The other five antibodies variably blocked the binding of both K3-4C8-K3-2F2 and B5-B3, suggesting that these epitopes are closely spaced and perhaps part of a single neutralization immunogenic site. Several combinations of monoclonal antibodies blocked the binding of polyclonal human convalescent antibody by greater than 96%, indicating that the neutralization epitopes bound by these antibodies are immunodominant in humans. Spontaneously arising HM-175 mutants were selected for resistance to monoclonal antibody-mediated neutralization. Fourteen clonally isolated mutants demonstrated substantial resistance to multiple monoclonal antibodies, including K3-4C8-K3-2F2 and B5-B3. In addition, 13 mutants demonstrated a 10-fold or greater reduction in neutraliztion mediated by polyclonal human antibody. Neutralization resistance was associated with reduced antibody binding. These results suggest that hepatitis A virus may differ from poliovirus in possessing a single, dominant neutralization immunogenic site and therefore may be a better candidate for synthetic peptide or antiidiotype vaccine development.

This article has been cited by other articles:

• Aragones, L., Bosch, A., Pinto, R. M. (2008). Hepatitis A Virus Mutant Spectra under the Selective Pressure of Monoclonal Antibodies: Codon Usage Constraints Limit Capsid Variability. J. Virol. 82: 1688-1700 [Abstract] [Full Text]  
• Nainan, O. V., Xia, G., Vaughan, G., Margolis, H. S. (2006). Diagnosis of Hepatitis A Virus Infection: a Molecular Approach. Clin. Microbiol. Rev. 19: 63-79 [Abstract] [Full Text]  
• Costa-Mattioli, M., Napoli, A. D., Ferre, V., Billaudel, S., Perez-Bercoff, R., Cristina, J. (2003). Genetic variability of hepatitis A virus. J. Gen. Virol. 84: 3191-3201 [Abstract] [Full Text]  
• Costa-Mattioli, M., Cristina, J., Romero, H., Perez-Bercof, R., Casane, D., Colina, R., Garcia, L., Vega, I., Glikman, G., Romanowsky, V., Castello, A., Nicand, E., Gassin, M., Billaudel, S., Ferre, V. (2002). Molecular Evolution of Hepatitis A Virus: a New Classification Based on the Complete VP1 Protein. J. Virol. 76: 9516-9525 [Abstract] [Full Text]  
• Silberstein, E., Dveksler, G., Kaplan, G. G. (2001). Neutralization of Hepatitis A Virus (HAV) by an Immunoadhesin Containing the Cysteine-Rich Region of HAV Cellular Receptor-1. J. Virol. 75: 717-725 [Abstract] [Full Text]  
• LaBrecque, F. D., LaBrecque, D. R., Klinzman, D., Perlman, S., Cederna, J. B., Winokur, P. L., Han, J.-Q., Stapleton, J. T. (1998). Recombinant Hepatitis A Virus Antigen: Improved Production and Utility in Diagnostic Immunoassays. J. Clin. Microbiol. 36: 2014-2018 [Abstract] [Full Text]